3 New Strong Buy Ratings from Top-Rated Analysts: 10/02/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Expedia Group (EXPE): Top travel stock with 60% upside targets
• Sk Hynix (SKHY): AI memory demand driving a 70%+ upside call
• Jazz Pharmaceuticals (JAZZ): 17 analysts back this growth story

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Expedia Group (NASDAQ: EXPE)

With travel demand rebounding and the company trading well below its 52-week high, EXPE presents a compelling value opportunity in the recovering travel sector.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $263.72 — get current quote

Max 1-year forecast: $430.00

Why we're watching:

• EXPE has solid, bullish coverage among the analysts we track, with 5 Strong Buy, 3 Buy, and 12 Hold recommendations. See all recommendations here
• For example, Evercore ISI Group researcher Mark Mahaney (a top 3% rated analyst) maintained his Buy rating with a price target suggesting the stock could see greater than 60% upside in the coming year. 
• It’s our Stock of the Week, with Editor-in-Chief Steve Reitmeister urging investors to buy if they believe oil prices will come down. (See his full coverage here.)
• Industry ranking context: EXPE is currently the #1 highest-rated stock in the Travel industry.
• Zen Ratings highlights: EXPE earns an overall A rating, equal to a Strong Buy recommendation. Stocks in this elite tier have historically delivered nearly 30% annual returns, significantly outpacing the S&P 500.
• Component Grades: EXPE excels with dual A grades for Financials and Value, reflecting the company's strong profit margin of 20.3% and attractive valuation metrics, while also maintaining a solid B for Artificial Intelligence, positioning it well as technology transforms the travel booking landscape. See all 7 Component Grades here

2. Sk Hynix (NASDAQ: SKHY)

With an exceptional profit margin of 76.7% and surging demand for high-bandwidth memory in AI applications, SKHY stands at the forefront of the semiconductor boom.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $184.60 — get current quote

Max 1-year forecast: $320.00

Why we're watching:

• SKHY has strong, bullish coverage among the analysts we track, with 5 Strong Buy and 4 Buy recommendations. See all recommendations here
• For example, Rosenblatt researcher Kevin Cassidy (a top 1% rated analyst) initiated coverage with a Strong Buy recommendation and price target that suggests the stock could see greater than 70% upside in the coming year. 
• Five additional top-tier analysts covering SKHY include Needham's Quinn Bolton, Wolfe Research's Chris Caso, RBC Capital's Srini Pajjuri, Cantor Fitzgerald's C.J. Muse, and Barclays' Simon Coles — all maintaining bullish outlooks on the memory sector's growth.
• Industry ranking context: SKHY is currently the #2 highest-rated stock in the Semiconductor industry, which has an Industry Rating of A.
• Zen Ratings highlights: SKHY secures an overall A rating, representing a Strong Buy recommendation. This grade reflects the elite top 5% of all stocks tracked based on a comprehensive 115-factor fundamental review.
• Component Grades: SKHY demonstrates exceptional strength with A grades for both Financials and Value, reflecting stellar operational metrics and attractive pricing relative to growth prospects, complemented by solid Bs for Artificial Intelligence, Growth, and Sentiment, underscoring its strategic position in next-generation memory technologies. See all 7 Component Grades here

3. Jazz Pharmaceuticals (NASDAQ: JAZZ)

Following its recent Actio Biosciences acquisition and with zanidatamab targeting a $3B-$5B market opportunity, JAZZ is well-positioned to expand its oncology franchise beyond its current $1B revenue milestone.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $232.35 — get current quote

Max 1-year forecast: $337.00

Why we're watching:

• JAZZ has strong, bullish coverage among the analysts we track, with 13 Strong Buy, 4 Buy, and 1 Hold recommendations. See all recommendations here
• Both Goldman Sachs researcher Andrea Newkirk (a top 22% rated analyst) and UBS researcher Ashwani Verma (a top 11% rated analyst) both maintain Strong Buy recommendations with twin price targets suggesting the stock could see roughly 45% upside in the coming year. 
• Seven additional top 20% analysts covering JAZZ all maintain bullish stances on the company's oncology pipeline and commercial execution.
• Industry ranking context: JAZZ is currently the #13 highest-rated stock in the Biotech industry. 
• Zen Ratings highlights: JAZZ achieves an overall A rating, which translates to a Strong Buy recommendation. Stocks earning this distinction represent the top 5% of the market based on a rigorous 115-factor fundamental assessment.
• Component Grades: JAZZ stands out with an A for Value, reflecting its attractive valuation relative to its growth trajectory and blockbuster pipeline potential, while also earning respectable Bs for Artificial Intelligence, Financials, Growth, and Momentum, indicating solid fundamentals across multiple dimensions. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.